Abstract : Gastric cancers GC with methylation of multiple CpG islands have a CpG island methylator phenotype CIMP and they can have different biological features. The aim of this study was to investigate the DNA methylation status of GCs and its association with their clinicopathological features. We evaluated the methylation status of four genes MINT1, MINT2, MINT25 and MINT31 in 105 primary GCs using bisul te-pyrosequencing analysis. We classi ed tumors as CIMPhigh CIMP-H , CIMP-low CIMP-L or CIMP-negative CIMP-N based on the methylation of MINT1, MINT2, MINT25, and MINT31. Overall, the prevalence of CIMP-H, CIMP-L and CIMP-N was 22% 23/105 , 52% 55/105 and 26% 27/105 , respectively. We observed a signi cant difference in tumor stage stages I-II vs. stages III-IV between CIMP-H and CIMP-N tumors P 0.0435 . No significant differences were observed in clinicopathological characteristics gender, age, location and tumor differentiation among the CIMP phenotypes. The prognoses of patients with a CIMP-H tumor is likely to be better than those with CIMP-L or CIMP-N tumors, but these differences are not statistically signi cant P 0.074 and P 0.200 . Our results suggest that CIMP may de ne a subgroup of GCs with distinct biological features.
Introduction
Gastric cancer GC arises from native gastric or metaplastic mucosa and is one of the most common malignancies worldwide 1 . Both genetic and epigenetic alterations in a variety of tumor suppressor and tumor-related genes have functional roles during carcinogenesis. Changes in DNA methylation status are epigenetic events and represent the most common molecular alteration in human neoplasia 2 . These changes in DNA methylation in cancer are classi ed as either genome-wide hypomethylation or gene promoter hypermethylation.
Promoter hypermethylation that leads to epigenetic silencing of multiple genes is an important mechanism in gastrointestinal carcinogenesis. Methylation of CpG dinucleotide-rich areas, termed CpG islands, occurs within the promoters of approximately 60% of human genes 3 . These CpG islands are usually associated with long-term, irreversible, epigenetic silencing of X-linked and imprinted genes as well as tumor-related genes 2 . The concordant hypermethylation of multiple genes is termed the CpG island methylator phenotype CIMP , and has been described in various cancers [4] [5] [6] [7] . Recent studies have demonstrated that GCs can be classi ed as CIMP-high CIMP-H , CIMP-low CIMP-L and CIMP-negative CIMP-N and that GCs with CIMP-H are associated with proximal tumor location, Epstein-Bar virus infection status and longer patient survival time 8 .
Original
The aim of this study was to evaluate the status of CIMP in primary GCs and to characterize the relationships between methylation status and clinicopathological features.
Materials and Methods

Patients and specimens
We collected a total of 105 primary GCs and 74 normal gastric mucosal tissues from 105 patients. All tissue specimens were obtained by endoscopic biopsy before treatment at Showa University Hospital. Corresponding adjacent normal-mucosa tissue specimens were also obtained from each patient case. Tumors were selected solely on the basis of availability. The ethics committee of Showa University School of Medicine approved the collection of tissue specimens.
Tissue specimens and DNA preparation
We examined 179 frozen tissue specimens 105 cancers and 74 adjacent normal-mucosa tissues from 105 GC patients. Frozen tissue specimens were harvested by endoscopic biopsy and stored at 80 until use. DNA was isolated from the frozen tissue specimens using standard proteinase K-phenol-chloroform extraction 9 or a QIAamp DNA mini kit QIAGEN, Inc., Germantown, MD, U.S.A. .
Methylation-related genes and de nition of CIMP
We studied the methylation status of four clones: MINT1, MINT2, MINT25 and MINT31. Firstly, we treated DNA methylation as a continuous variable. To de ne CIMP, however, we converted the continuous values into categorical variables positive/negative , as defined by a methylation density greater than 15%. We classi ed GCs into three groups CIMP-H, CIMP-L and CIMP-N , based on their methylation status of the promoters in CpG islands of MINT1, MINT2, MINT25, and MINT31. Tumors were classi ed as CIMP-H if three or more of these marker gene promoters were methylated ; as CIMP-L if one or two marker gene promoters were methylated ; and all other tumors were de ned as CIMP-N.
Bisul te PCR and pyrosequencing analysis of DNA methylation
Bisul te treatment was carried out as previously described 10 . Aliquots of 2 or 3 L of bisulte-treated DNA were used as the template for the bisul te polymerase chain reaction PCR . The sequences of primers and the PCR conditions used to amplify speci c DNA fragments of various target genes have been reported previously 11, 12 . The protocol for pyrosequencing was previously described in detail 13 . Pyrosequencing measures the methylation status of several CpG sites in DNA. Usually, these different sites show highly concordant methylation. Therefore, we averaged the methylation percentage of all the CpG sites that we measured for each gene.
Data analysis and statistics
Continuous variables e.g., age were analyzed using the Mann-Whitney test. Categorical variables were compared between tumor groups using the 2 test or Fisher s exact test when testing small sample numbers. Survival was assessed using the Kaplan-Meier method. Survival curves were compared using the long-rank test. All tests were two sided, and P 0.05 was considered statistically signi cant.
Results
CIMP status and clinicopathological characteristics
The prevalence of CIMP-H, CIMP-L and CIMP-N among the 105 GCs was 22% 23/105 , 52% 55/105 and 26% 27/105 , respectively. Table 1 shows the relationship between CIMP status and clinicopathological characteristics of the patients with GC in this study. We observed a signi cant difference in stage early vs. late stage between CIMP-H and CIMP-N GC patients P 0.0435 , whereas no signi cant differences were observed in any other clinicopathological characteristics between patients with CIMP-H and CIMP-L/N GCs. The survival of patients with CIMP-H, CIMP-L and CIMP-N GCs was characterized using Kaplan-Meier analysis and was compared using the long-rank test It should be noted that these differences were not statistically signi cant P 0.074 and P 0.200, respectively .
Discussion
Toyota et al 14 proposed a definition of CIMP status in GCs that is based on the DNA methylation of the MINT markers, which were originally identi ed from colon cancer cells. GCs are classi ed as CIMP-L tumors and CIMP-H tumors, which are more likely to show distinct clinicopathological characteristics than CIMP-L tumors 8 . Several reports 8 14-17 have shown the prevalence of CIMP-H in GCs to range from 24% to 41% using MINT markers. The current study found CIMP-H in 22% of GCs using four MINT genes MINT1, MINT2, MINT25 and MINT31 . In other studies, CIMP was de ned by the DNA methylation status of tumor-related genes, rather than MINT genes [18] [19] [20] -methylguanine DNAmethyltransferase was linked to the responsiveness of brain tumors to alkylating agents. These positive relationships between the DNA methylation of cancer-related genes and therapeutic ef cacy might be implicated in the longer survival time of GC patients with CIMP-H. Our data shows that the survival time of GC patients with CIMP-H is likely to be longer than those with CIMP-L/CIMP-N GCs, but no statistical differences were observed in survival time among patients with different CIMP status. It should be noted that the proportion of patients at stages III-IV in the current study is higher than in the study by Kusano et al 77% vs. 56%, respectively 8 . As shown in Figure 1 , approximately half of the CIMP-H patients were terminated from the study for follow-up at 20 months. Nine patients died after chemotherapy or surgical resection followed by chemotherapy stage IV, eight patients ; stage IIIB, one patient , three patients all stage II moved to another hospital. These terminations from the study may have contributed to our failure to observe signi cant differences in survival among patients with different CIMP status. No signi cant difference was found in other parameters such as tumor location and histologic differentiation between GCs with CIMP-H vs. CIMP-L/CIMP-N. These observations could be explained by multiple factors, including : 1 about half of the samples in this study were stage IV GC, which more frequently show diffuse type cancer and shorter patient survival time than other types, independent of CIMP status 17 ; 2 EB-virus status was not examined in this study because EBV-positive CIMP-H GCs are more likely to be diffuse carcinomas or to be located proximally in the stomach, compared with EBV-negative tumors 8 ; 3 we used different CIMP-markers from previous studies. In summary, our data indicates that CIMP-H represents a specific subgroup of GCs with distinct biological features. Clari cation of the utility of CIMP status as a valuable prognostic marker for GCs awaits further study.
